Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B
Ascidian and Lilly signed a collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.
Will Maddox
Jun 3, 2026 7:00am
Roche oral SERD's 1st-line miss spurs new adjuvant trial
Jun 2, 2026 12:45pm
Roche nabs European approval for second Alzheimer’s test
May 12, 2026 7:07am
Roche shells out up to $1B for PathAI to boost AI diagnostics
May 7, 2026 9:30am
Fierce Pharma
Roche exec: Giredestrant may become company’s largest product
Apr 23, 2026 2:52pm
Roche CEO gives 3 reasons for sitting out Big Pharma M&A spree
Apr 23, 2026 5:18am
